報價延遲最少15分鐘:2024/05/13 16:16 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
24 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.28/-2.43
|
|
企業價值
4.05B
|
| 資產負債 |
|
每股賬面淨值
0.56
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
563.95M
|
|
每股收益
4.40
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/13 16:16 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD,test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |